- Corporate
- The share
- Press releases
- Financial calendar
- Financial reports
- Financial reports – ESEF
- Prospectus and material offerings
- Financial presentations
- Corporate governance
- Analyst Coverage
- Code of Conduct
- Environmental Policy
- Code of Conduct for Suppliers
- Privacy policy
- Contact us
- Subscribe
- Thank you
- Error
Conference call on Interim Report
Invitation to attend XVIVO Perfusion’s conference call regarding the presentation of the interim report July – September 2020. The presentation will be held in English.
Time: Friday, October 23, 2020 at 2.30 p.m. CET
Information regarding the conference can be found under the following link:
https://bluejeans.com/405912591
Phone numbers to the conference:
+46.8.5886.8700 (Sweden)
+46.850.513.580 (Sweden (Stockholm))
+44.203.608.5256 (UK (London)
+1.404.458.0105 (United States)
+47.2160.1825 (Norway (Oslo)
Global Numbers can be found under the link: https://www.bluejeans.com/numbers
Conference name: XVIVO Virtual call, conference ID: 405 912 591#
Participants from XVIVO Perfusion:
Dag Andersson, CEO
Christoffer Rosenblad, CFO
The telephone conference will be adminsitrated by Ulrik Trattner, Carnegie. To send a question, please email Ulrik.trattner@carnegie.se or use the chat function which you can find in the top right corner of the screen.
The press release for XVIVO Perfusion’s interim report July-September 2020 will be released on October 23, 2020 at 7:30 a.m. CET.
Before the conference call, slides will be available at the company web page, www.xvivoperfusion.com/corporate/.
October 16, 2020
Gothenburg
XVIVO Perfusion AB (publ)
For further information please contact:
Dag Andersson, CEO, +46 76 643 30 31, e-post: dag.andersson@xvivoperfusion.com
Christoffer Rosenblad, CFO, +46 73 519 21 59 e-post: christoffer.rosenblad@xvivoperfusion.com
About Us
XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation. The company is headquartered in Gothenburg, Sweden, and has one office in Lund, Sweden, one office in Groningen, the Netherlands and one office in Denver, USA. The XVIVO share is listed on Nasdaq Stockholm and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com.
